Cannabidiol is a substance that can be obtained from Cannabis sativa L. plants and be synthesised chemically as well. The European Commission considers that CBD qualifies as a novel food provided it meets the conditions of EU legislation on novel foods. Following the submission of numerous applications for CBD under the novel food regulation, the Commission asked EFSA to give its opinion on whether CBD consumption is safe for humans.

There is insufficient data on the effect of CBD on the liver, gastrointestinal tract, endocrine system, nervous system and on people’s psychological well-being. Studies in animals show significant adverse effects especially in relation to reproduction. It is important to determine if these effects are also seen in humans.

EFSA is holding an info-session, open to applicants and other groups or individuals with an interest in this issue and novel food more generally. The online event takes place on 28 June – registration is open until 17 June.

Source: https://www.efsa.europa.eu/en/news/cannabidiol-novel-food-evaluations-hold-pending-new-data

The news was shared by the EFSA Focal Point, run by Nébih and EFSA.